Table 5 New drugs (DAA combinations) for the treatment of hepatitis C in phase II study
From: Treatment of hepatitis C virus infection in the future
Drug name/category | Drug name/category | Company |
|---|---|---|
ABT-450r/Protease inhibitor | ABT-072/Polymerase inhibitor | Abbott/Enanta |
ABT-450r/Protease inhibitor | ABT-267/NS5A inhibitor | Abbott/Enanta |
ABT-450r/Protease inhibitor | ABT-333/Polymerase inhibitor | Abbott/Enanta |
Daclatasvir (BMS-79002)/ NS5A inhibitor | Sofosbuvir (GS-7977)/ Polymerase inhibitor | Bristol-Myers Squibb/Gilead |
Daclatasvir (BMS-79002)/ NS5A inhibitor | Simeprevir (TMC435)/ Protease inhibitor | Bristol-Myers Squibb/Janssen |
Danoprevir (RG7227)/ Protease inhibitor | Setrobuvir (ANA 598)/ Polymerase inhibitor | Genentech |
Danoprevir (RG7227)/ Protease inhibitor | Mericitabine (RG7128)/ Polymerase inhibitor | Genentech |
GS-9256 | Tegobuvir (GS-9190)/ Polymerase inhibitor | Gilead |
Incivek (Telaprevir)/ Protease inhibitor | VX-222/Polymerase inhibitor | Vertex |
Mericitabine (RG7128)/ Polymerase inhibitor | Incivek (Telaprevir)/ Protease inhibitor | Genentech/Vertex |
Simeprevir (TMC435)/ Protease inhibitor | Daclatasvir (BMS-79002)/ NS5A inhibitor | Janssen/Bristol-Myers Squibb |
Simeprevir (TMC435)/ Protease inhibitor | Sofosbuvir (GS-7977)/ Polymerase inhibitor | Janssen/ Gilead |
Simeprevir (TMC435)/ Protease inhibitor | TMC647055/NNI inhibitor/Ritonavir | Janssen |
Sofosbuvir (GS-7977)/ Polymerase inhibitor | GS-5885/ NS5A inhibitor | Gilead |
VX-135/Polymerase inhibitor | GSK2336805/ NS5A inhibitor | Vertex/GSK |
VX-135/Polymerase inhibitor | Simeprevir (TMC435)/ Protease inhibitor | Vertex/Janssen |